Boditech Med (KOSDAQ:A206640) - Share price, News & Analysis

A206640 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	3/6

A206640 Stock Overview

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents.

Rewards

Trading at 70.8% below our estimate of its fair value

Risk Analysis

Unstable dividend track record

Boditech Med Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Boditech Med
Historical stock prices
Current Share Price	₩13,900.00
52 Week High	₩26,800.00
52 Week Low	₩13,600.00
Beta	-0.71
1 Month Change	-10.32%
3 Month Change	-6.71%
1 Year Change	-28.54%
3 Year Change	25.79%
5 Year Change	-27.79%
Change since IPO	-75.02%

Recent News & Updates

Apr 16

Boditech Med Inc. (KOSDAQ:206640) Shares Fly 49% But Investors Aren't Buying For Growth

Boditech Med Inc. ( KOSDAQ:206640 ) shares have had a really impressive month, gaining 49% after a shaky period...

Shareholder Returns

	A206640	KR Medical Equipment	KR Market
7D	-3.1%	0.8%	1.2%
1Y	-28.5%	-4.7%	-14.3%

Return vs Industry: A206640 underperformed the KR Medical Equipment industry which returned -4.7% over the past year.

Return vs Market: A206640 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A206640's price volatile compared to industry and market?
A206640 volatility
A206640 Average Weekly Movement	6.4%
Medical Equipment Industry Average Movement	5.6%
Market Average Movement	5.4%
10% most volatile stocks in KR Market	10.2%
10% least volatile stocks in KR Market	3.1%

Stable Share Price: A206640 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A206640's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	391	n/a	https://www.boditech.co.kr

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer that measures the concentration of targeted analytes in body fluids, such as blood, urine, and other samples; and ichroma M2, a portable analyzer intended to be used with in vitro diagnostic immunofluorescent assay kits for screening, monitoring and/or examining routine physics in centralized laboratories of hospitals or physician’s clinics. The company also provides Ichroma TRIAS Reader, an in vitro diagnostic device that measures the concentration of targeted analyte from various samples, such as blood, nasal swabs, and nasopharyngeal swabs; Hemochroma PLUS, an in vitro diagnostic device to quantitative test total hemoglobin concentration in the blood; i-chamber, an auxiliary device for the ichroma systems; and HandyRay, a laser device for the capillary blood sampling without a needle.

Boditech Med Fundamentals Summary

How do Boditech Med's earnings and revenue compare to its market cap?
A206640 fundamental statistics
Market Cap	₩319.66b
Earnings (TTM)	₩44.37b
Revenue (TTM)	₩157.71b

7.1x

P/E Ratio

2.0x

P/S Ratio

Is A206640 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A206640 income statement (TTM)
Revenue	₩157.71b
Cost of Revenue	₩59.52b
Gross Profit	₩98.19b
Other Expenses	₩53.83b
Earnings	₩44.37b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	1.96k
Gross Margin	62.26%
Net Profit Margin	28.13%
Debt/Equity Ratio	3.2%

How did A206640 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

10%

Payout Ratio

Valuation

Is Boditech Med undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: A206640 (₩13900) is trading below our estimate of fair value (₩47586.89)

Significantly Below Fair Value: A206640 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: A206640 is good value based on its Price-To-Earnings Ratio (7.1x) compared to the KR Medical Equipment industry average (13.6x).

PE vs Market: A206640 is good value based on its Price-To-Earnings Ratio (7.1x) compared to the KR market (14.1x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A206640's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A206640 is good value based on its Price-To-Book Ratio (2.1x) compared to the KR Medical Equipment industry average (2.4x).

Future Growth

How is Boditech Med forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

4.7%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Boditech Med has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Boditech Med performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

57.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A206640 has high quality earnings.

Growing Profit Margin: A206640's current net profit margins (28.1%) are lower than last year (31.6%).

Past Earnings Growth Analysis

Earnings Trend: A206640's earnings have grown significantly by 57.2% per year over the past 5 years.

Accelerating Growth: A206640's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A206640 had negative earnings growth (-2.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (15.1%).

Return on Equity

High ROE: A206640's Return on Equity (29.4%) is considered high.

Financial Health

How is Boditech Med's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: A206640's short term assets (₩131.1B) exceed its short term liabilities (₩27.1B).

Long Term Liabilities: A206640's short term assets (₩131.1B) exceed its long term liabilities (₩3.9B).

Debt to Equity History and Analysis

Debt Level: A206640 has more cash than its total debt.

Reducing Debt: A206640's debt to equity ratio has reduced from 3.5% to 3.2% over the past 5 years.

Debt Coverage: A206640's debt is well covered by operating cash flow (969.5%).

Interest Coverage: A206640 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Boditech Med current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

1.44%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A206640's dividend (1.44%) is higher than the bottom 25% of dividend payers in the KR market (0.84%).

High Dividend: A206640's dividend (1.44%) is low compared to the top 25% of dividend payers in the KR market (2.75%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, A206640 has been paying a dividend for less than 10 years.

Growing Dividend: A206640's dividend payments have increased, but the company has only paid a dividend for 3 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (10.3%), A206640's dividend payments are thoroughly covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (14.3%), A206640's dividend payments are thoroughly covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Boditech Med has no CEO, or we have no data on them.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31